Related Experiment Video

Updated: Sep 1, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis

Aswin Srinivasan1, Jonathan Brown1, Pavitra Parimala Krishnamani2

  • 1Department of Internal Medicine, HCA Kingwood/University of Houston College of Medicine, Kingwood, TX, United States of America.

American Heart Journal Plus : Cardiology Research and Practice
|August 16, 2022
PubMed

Insights

Low-dose aspirin (ASA) use is associated with a reduced risk of in-hospital mortality in patients with COVID-19. This meta-analysis of over 164,000 patients confirms aspirin

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Thromboembolism is a significant cause of mortality in COVID-19 patients.
  • Existing studies on aspirin (ASA) and COVID-19 mortality show conflicting results.
  • Evidence regarding aspirin's impact on COVID-19-related thromboembolic events is inconsistent.

Purpose of the Study:

  • To investigate the association between low-dose aspirin use and in-hospital mortality in COVID-19 patients.
  • To synthesize evidence from multiple studies to clarify aspirin's role in reducing COVID-19 mortality.
  • To provide a comprehensive analysis of aspirin's effect on mortality in a large COVID-19 patient cohort.

Main Methods:

  • Aggregate data meta-analysis of fourteen studies.
  • Inclusion of 164,539 COVID-19 patients.
  • Analysis of risk ratios (RR), hazard ratios (HR), and pooled effect size.

Main Results:

  • A reduced risk of in-hospital mortality was observed with aspirin use.
  • Eight studies reporting RR showed a pooled RR of 0.90 (95% CI 0.82-0.98).
  • Six studies reporting HR showed a pooled HR of 0.56 (95% CI 0.41-0.76).
  • The overall pooled effect size indicated a significant reduction in mortality (0.71; 95% CI 0.59-0.85).

Conclusions:

  • Low-dose aspirin is associated with a reduced risk of in-hospital mortality in COVID-19 patients.
  • The findings support the potential benefit of aspirin in managing COVID-19.
  • Further research may be warranted to confirm these findings and guide clinical practice.

Keywords:
ASA, Acetylsalicylic acidAnti-thrombotic therapyAspirinCOVID-19MortalityNOS, Newcastle-Ottawa scaleThromboembolism

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

687
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
621
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
23
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
28
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
28